Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy

Loren K. Mell, David A. Schomas, Joseph K. Salama, Kiran Devisetty, Bulent Aydogan, Robert C. Miller, Ashesh B. Jani, Hedy L. Kindler, Arno J. Mundt, John C. Roeske, Steven J. Chmura

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive. Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V5, V10, V15, and V20 were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V10, V15, and V20 (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.

Original languageEnglish (US)
Pages (from-to)1431-1437
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume70
Issue number5
DOIs
StatePublished - Apr 1 2008

Fingerprint

Anus Neoplasms
Intensity-Modulated Radiotherapy
bone marrow
Pelvic Bones
chemotherapy
toxicity
radiation therapy
Bone Marrow
cancer
Drug Therapy
blood cell count
leukocytes
Leukocyte Count
neutrophils
regression analysis
lymphatic system
Chemoradiotherapy
Neutrophils
leukopenia
Lymph Nodes

Keywords

  • Anal cancer
  • Bone marrow
  • Hematologic toxicity
  • IMRT
  • V

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. / Mell, Loren K.; Schomas, David A.; Salama, Joseph K.; Devisetty, Kiran; Aydogan, Bulent; Miller, Robert C.; Jani, Ashesh B.; Kindler, Hedy L.; Mundt, Arno J.; Roeske, John C.; Chmura, Steven J.

In: International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 5, 01.04.2008, p. 1431-1437.

Research output: Contribution to journalArticle

Mell, Loren K. ; Schomas, David A. ; Salama, Joseph K. ; Devisetty, Kiran ; Aydogan, Bulent ; Miller, Robert C. ; Jani, Ashesh B. ; Kindler, Hedy L. ; Mundt, Arno J. ; Roeske, John C. ; Chmura, Steven J. / Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy. In: International Journal of Radiation Oncology Biology Physics. 2008 ; Vol. 70, No. 5. pp. 1431-1437.
@article{280c4c3dbd0f4e00a6591dd1608c64e3,
title = "Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy",
abstract = "Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42{\%}) had Stage T3-4 disease; 15 patients (31{\%}) were node positive. Overall, 27 (56{\%}), 24 (50{\%}), 4 (8{\%}), and 13 (27{\%}) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V5, V10, V15, and V20 were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V10, V15, and V20 (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.",
keywords = "Anal cancer, Bone marrow, Hematologic toxicity, IMRT, V",
author = "Mell, {Loren K.} and Schomas, {David A.} and Salama, {Joseph K.} and Kiran Devisetty and Bulent Aydogan and Miller, {Robert C.} and Jani, {Ashesh B.} and Kindler, {Hedy L.} and Mundt, {Arno J.} and Roeske, {John C.} and Chmura, {Steven J.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2007.08.074",
language = "English (US)",
volume = "70",
pages = "1431--1437",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy

AU - Mell, Loren K.

AU - Schomas, David A.

AU - Salama, Joseph K.

AU - Devisetty, Kiran

AU - Aydogan, Bulent

AU - Miller, Robert C.

AU - Jani, Ashesh B.

AU - Kindler, Hedy L.

AU - Mundt, Arno J.

AU - Roeske, John C.

AU - Chmura, Steven J.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive. Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V5, V10, V15, and V20 were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V10, V15, and V20 (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.

AB - Purpose: To test the hypothesis that the volume of pelvic bone marrow (PBM) receiving 10 and 20 Gy or more (PBM-V10 and PBM-V20) is associated with acute hematologic toxicity (HT) in anal cancer patients treated with concurrent chemoradiotherapy. Methods and Materials: We analyzed 48 consecutive anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiation therapy. The median radiation dose to gross tumor and regional lymph nodes was 50.4 and 45 Gy, respectively. Pelvic bone marrow was defined as the region extending from the iliac crests to the ischial tuberosities, including the os coxae, lumbosacral spine, and proximal femora. Endpoints included the white blood cell count (WBC), absolute neutrophil count (ANC), hemoglobin, and platelet count nadirs. Regression models with multiple independent predictors were used to test associations between dosimetric parameters and HT. Results: Twenty patients (42%) had Stage T3-4 disease; 15 patients (31%) were node positive. Overall, 27 (56%), 24 (50%), 4 (8%), and 13 (27%) experienced acute Grade 3-4 leukopenia, neutropenia, anemia, and thrombocytopenia, respectively. On multiple regression analysis, increased PBM-V5, V10, V15, and V20 were significantly associated with decreased WBC and ANC nadirs, as were female gender, decreased body mass index, and increased lumbosacral bone marrow V10, V15, and V20 (p < 0.05 for each association). Lymph node positivity was significantly associated with a decreased WBC nadir on multiple regression analysis (p < 0.05). Conclusion: This analysis supports the hypothesis that increased low-dose radiation to PBM is associated with acute HT during chemoradiotherapy for anal cancer. Techniques to limit bone marrow irradiation may reduce HT in anal cancer patients.

KW - Anal cancer

KW - Bone marrow

KW - Hematologic toxicity

KW - IMRT

KW - V

UR - http://www.scopus.com/inward/record.url?scp=40949099019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949099019&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.08.074

DO - 10.1016/j.ijrobp.2007.08.074

M3 - Article

C2 - 17996390

AN - SCOPUS:40949099019

VL - 70

SP - 1431

EP - 1437

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -